Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Share News (APH)

  • This share is currently suspended. It was suspended at a price of 64.70
  • There is currently no data for APH

Small Cap round-up: Vislink, Source BioScience, Alliance Pharma..........

Wed, 24th Mar 2010 18:43
New chief executive Duncan Lewis has restructured Vislink's operations so they are based on customer sectors rather than technologies. The core news and entertainment division reported much lower revenues as its major US contract came to an end. The law enforcement division is benefiting from increased spending on surveillance equipment and the marine division is gaining work onshore. Revenues fell from £101m to £94.7m in 2009. The underlying operating profit declined by two-fifths to £5.22m and pre-tax profit slumped from £8.77m to £4.75m. The dividend is unchanged at 1.25p a share. Net cash was £611,000 at the end of 2009. Capitalised development spending increased from £2.95m to £3.2m. The order book was worth £20.3m at the end of 2009. Cost savings will help profits to recover this year. Evolution forecasts that profits will improve to £8.6m in 2010. Asia and the Middle East provide the most opportunities. Vislink is ready to make acquisitions and they are likely to be in Asia so that the company has a base in the region. Healthcare and life sciences services provider Source BioScience moved into profit in 2009. There was a swing from a loss of £300,000 to a profit of £200,000 on revenues that were 11% higher at £12.7m. All three divisions made a positive contribution in the year. Source is investing in DNA sequencing equipment and expects this to be a growth area. The outsourced pharma services operation made its first profit. Alliance Pharma reported a 44% increase in revenues to £31.2m in 2009 thanks to a combination of organic and acquisitive growth. Pre-exceptional profits jumped from £2.4m to £8.6m, although that doesn't include a £2.8m write-off mainly relating to the capitalised development costs of a drug. Alliance specialises in mature drugs and treatments which have a solid revenue base. Some of its drugs are more than 50 years old but they still have significant revenues. The recent purchase of Cambridge Laboratories for up to £16.4m has added cancer drugs to the portfolio. A much-improved second half performance helped eg solutions to return to profit in the year to January 2010. The operations management software supplier reported a 13% increase in revenues to £4.15m. A loss of £753,000 was turned into a profit of £99,000 in 2009. Higher gross margins and cost cutting were behind the improvement. More software licences were sold in the most recent period. Weak construction demand has hit trading at quantity surveyor Baqus and although work is being won it is at lower margins than in the past. The order book is flat at £8m. Management had already warned that the interim figures would be disappointing. Revenues fell from £3.98m to £3.85m in the six months to December 2009. A profit of £365,000 has turned into a loss of £470,000, including an exceptional charge for redundancies and office closures.

Related News

Alliance Pharma loss narrows in 2024 due to reduced impairment charges
8 Apr 2025

Alliance Pharma loss narrows in 2024 due to reduced impairment charges

(Alliance News) - Alliance Pharma PLC on Tuesday reported a narrowed loss for 2024 despite a decline in revenue, due to a reduction in impairment char...

Alliance Pharma confident despite softer sales
8 Apr 2025

Alliance Pharma confident despite softer sales

(Sharecast News) - Alliance Pharma posted weaker full-year revenues on Tuesday, but insisted it remained well-positioned for medium-term growth.

Alliance Pharma board backs final GBP362 million takeover bid
10 Mar 2025

Alliance Pharma board backs final GBP362 million takeover bid

(Alliance News) - Alliance Pharma PLC on Monday said it has agreed to a final increased cash offer of 64.75 pence per share from Dbay Advisors Ltd and...

Alliance Pharma News

Alliance Pharma Trading In Line With Expectations
21 May 2014

Alliance Pharma Trading In Line With Expectations

LONDON (Alliance News) - Alliance Pharma PLC Wednesday said trading in the first four months of 2014 has been in line with expectations, following a r...

Wednesday broker round-up UPDATE
21 May 2014

Wednesday broker round-up UPDATE

African Minerals: Citi reduces target price from 260p to 190p, while leaving its buy recommendation unchanged. Alliance Pharma: Numis lowers target p...

Alliance Pharma's 2013 pre-tax profit rises
26 Mar 2014

Alliance Pharma's 2013 pre-tax profit rises

Alliance Pharma's annual pre-tax profit gained 11 per cent to 12m pounds, on the back of three acquisitions. The pharmaceutical company reported a 1...

Alliance Pharma Lifts Its 2013 Dividend As Profit And Margins Rise
26 Mar 2014

Alliance Pharma Lifts Its 2013 Dividend As Profit And Margins Rise

LONDON (Alliance News) - Alliance Pharma PLC raised its dividend as it saw pretax profit rise in 2013, benefiting from improved margins and growth in ...

UK BROKER RATINGS: Liberum Raises FirstGroup, Cuts Go-Ahead
26 Mar 2014

UK BROKER RATINGS: Liberum Raises FirstGroup, Cuts Go-Ahead

LONDON (Alliance News) - The following UK shares received analyst recommendations Wednesday morning:----------FTSE 100----------UBS CUTS ITV TO 'NEUTR...

Wednesday broker round-up UPDATE
26 Mar 2014

Wednesday broker round-up UPDATE

Aberdeen Asset Management: Citi reduces target price from 455p to 390p and stays with its neutral rating. Acta: Cantor Fitzgerald places both its tar...